Gold Standard:Pathology confirms

7 trials

Sponsors

Peking University Shenzhen Hospital, PEKING UNIVERSITY SHENZHEN HOSPITAL

Conditions

Malignant tumors that have been pathologically diagnosed or are suspected by clinical manifestations and other imaging examinations to require a definitive diagnosis.Patients with neuroendocrine tumors (NENs) originating from the gastrointestinal pancreas, lung, neural crest, or with an unknown primary source, who require diagnosis or are suspected.Patients with suspected malignant tumors not diagnosed by other methodsProstate cancerThose suspected of having a malignant tumor of bone after biopsy or CT or MRI examinationpatients requiring diagnosis or suspected of having ccRCC.

Unknown Phase

68Ga-FAPI-RGD PET/CT or 18F-AlF-FAPI-RGD PET/CT in the diagnosis of malignant tumors: a cross-sectional, diagnostic clinical study

Active, not recruitingChiCTR2500096350

Peking University Shenzhen HospitalPatients with suspected malignant tumors not diagnosed by other methods

Start: 2025-01-31Updated: 2025-01-27

18F/89Zr-RANKL PET/CT in multiple myeloma and bone metastases: a diagnostic trial with a cross-sectional study design

Active, not recruitingChiCTR2500096744

Peking University Shenzhen HospitalThose suspected of having a malignant tumor of bone after biopsy or CT or MRI examination

Start: 2025-03-01Updated: 2025-02-10

A diagnostic trial study evaluating the sensitivity and specificity of SSTRP PET/CT imaging with a novel targeted somatostatin receptor for the diagnosis of neuroendocrine tumors.

Active, not recruitingChiCTR2500098003

PEKING UNIVERSITY SHENZHEN HOSPITALPatients with neuroendocrine tumors (NENs) originating from the gastrointestinal pancreas, lung, neural crest, or with an unknown primary source, who require diagnosis or are suspected.

Start: 2025-03-01Updated: 2025-03-03

The trial study of novel targeted carbonic anhydrase IX PET/CT imaging for the diagnosis of clear cell renal cell carcinoma.

Active, not recruitingChiCTR2500100742

Peking University Shenzhen Hospitalpatients requiring diagnosis or suspected of having ccRCC.

Start: 2025-04-15Updated: 2025-04-21

Targeted Trop2 PET Visualizers [18F]AlF-RESCA-T4 or [68Ga]Ga-NOTA-T4 in the Diagnosis of Malignant Tumors: a Cross-Sectional, Diagnostic Clinical Study

Active, not recruitingChiCTR2500100741

PEKING UNIVERSITY SHENZHEN HOSPITALPatients with suspected malignant tumors not diagnosed by other methods

Start: 2025-04-15Updated: 2025-04-21

Application of FAPI and 18F-FDG dual tracer single PET imaging in the diagnosis of malignant tumors: a cross-sectional, diagnostic clinical study

Active, not recruitingChiCTR2500107647

PEKING UNIVERSITY SHENZHEN HOSPITALMalignant tumors that have been pathologically diagnosed or are suspected by clinical manifestations and other imaging examinations to require a definitive diagnosis.

Start: 2025-08-15Updated: 2025-08-18

A Diagnostic Trial Study of Novel PET/CT Imaging Targeting Acid Phosphatase for Prostate Cancer

RecruitingChiCTR2600125732

Peking University Shenzhen HospitalProstate cancer

Start: 2026-05-31Updated: 2026-06-01